"I love Disc Medicine: New Therapies for Rare Blood Disorders"

2022-09-06 16:57:31

Skip to primary navigation Skip to main content Skip to footer Gemini Therapeutics and Disc Medicine Announce Definitive Merger Agreement Read More Our VisionOur ScienceOur PipelineOverviewBitopertinDISC-0974Mat-2 InhibitorPublications and Supporting LiteratureOur TeamNewsCareers Focused on Hematology Dedicated to Patients Disc Medicine Initiates BEACON, a Phase 2 Clinical Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP) read more Innovation There are millions of patients whose lives are affected by and suffer from hematologic diseases. From rare blood disorders to widespread, chronic disorders, there are a host of diseases that require creative, new approaches and a willingness to pioneer new fields of biology. learn more about our science Impact We are committed to turning scientific discoveries into useful therapies that will have a meaningful impact on the lives of patients and their families. We are pursuing the development of treatments that will potentially save lives, alleviate suffering and enable patients to lead vibrant lives. learn more about our pipeline Inspiration Our team of talented scientists and industry veterans draws motivation and meaning from the work we do and the patients we hope to help. We are also inspired by a shared drive, tireless dedication and desire to make a difference that brings us together as colleagues. learn more about our team In The News Disc Medicine Initiates BEACON, a Phase 2 Clinical Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP) WATERTOWN, Mass. (August 10, 2022) – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutic candidates… read more Gemini Therapeutics and Disc Medicine Announce Merger Agreement WAYLAND, Mass. and WATERTOWN, Mass. (August 10, 2022) – Gemini Therapeutics, Inc. (Nasdaq: GMTX) (“Gemini”) and Disc Medicine, Inc. (“Disc”), a privately-held,… read more Disc Medicine Announces Presentation of Clinical Data from First-in-Human Phase 1 Study of DISC-0974 at European Hematology Association (EHA) 2022 Congress WATERTOWN, Mass. (May 16, 2022) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for… read more [email protected] Arsenal Street, Suite 101, Watertown, MA  02472© 2021 Disc Medicine All rights reserved.Terms of UsePrivacy Policy